Tag:
Cougar Biotechnology
Latest Headlines
Latest Headlines
Cougar founder snags Pfizer cancer drug, raises $55M and launches new biotech
The former CEO and founder of Cougar Biotechnology, Alan Auerbach, is back in the business of developing cancer drugs. In a series of maneuvers unveiled yesterday, Auerbach's Puma Biotechnology
FDA approves J&J's prostate cancer drug Zytiga
Johnson & Johnson's billion-dollar buyout of Cougar Biotech has paid off. The FDA has approved Zytiga (abiraterone acetate) in combination with prednisone for patients with late-stage
J&J unit's prostate cancer drug improves survival
A independent data monitoring committee has recommended that advanced prostate cancer patients in the placebo arm of a Phase III trial evaluating Ortho Biotech Oncology R&D's abiraterone acetate
J&J's prostate cancer drug proves promising in Ph2
A mid-stage trial for abiraterone--an oral drug which inspired a billion-dollar buyout less than a year ago --has produced another set of promising results for men with advanced, treatment-resistant
Cougar trial sees big response to prostate cancer drug
Cougar Biotechnology revealed some new clinical trial data this morning that helps explain why Johnson & Johnson is willing to pay nearly a billion dollars for the company. Researchers say that
J&J buys Cougar Biotech for $1B
Johnson & Johnson has snagged a biotech with a late-stage oncology drug in its pipeline. J&J will pay $1 billion cash for Los Angeles-based Cougar Biotechnology, which is developing drugs for
Researchers herald prostate cancer breakthrough
An early-stage prostate cancer therapy is being hailed by researchers for significantly improving outcomes for 250 refractive men who participated in a clinical trial. Abiraterone works by switching
